February 11, 2005 -- Stocks ended the trading week with a broad move higher. The Centient Biotech 200™ gained a substantial 1.9%, adding on 62.90 points to close at 3361.51. The rally did a lot to assuage the pain inflicted by the four earlier sessions of the week, all of which were losers. Nevertheless, the index remained at a 3% loss for the 5-day period. In stock news, Amgen put the final kibosh on a Parkinson’s drug because it causes brain damage, Alpharma and Ivax settled their dispute about generic Neurontin, Pfizer will cut $2 billion out of its sales force costs, GenVec will procede with tests of TNFerade against pancreatic cancer, but not other indications, Nymox will sell its Alzheimer’s diagnostic kit in Europe, and AlgoRx postponed its IPO--but for how long? We give details...
